Drug Major Dr Reddy'S On Saturday Said It Has Received Four Observations From The Us Health Regulator Usfda For Its Facility At Srikakulam In Andhra Pradesh. The Audit Of The Company'S Api Srikakulam Plant (Sez) By The United States Food And Drug Administration (Usfda) Was Completed On Friday, The Hyderabad-Based Pharma Major Said In A Regulatory Filing.Dr Reddy'S Further Said That It Would Address The Four Concerns Within The Stipulated Timeline."The Audit Of Our Api Srikakulam Plant (Sez), Andhra Pradesh, By The Usfda, Has Been Completed On October 25, 2019. We Have Been Issued A Form 483 With Four Observations," Said Dr Reddy'S.It Further Said: "We Will Address Them Comprehensively Within The Stipulated Timeline."As Per The Us Health Regulator, "An Fda Form 483 Is Issued To Firm Management At The Conclusion Of An Inspection When An Investigator(S) Has Observed Any Conditions That In Their Judgment May Constitute Violations Of The Food Drug And Cosmetic (Fd&C) Act And Related Acts."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!